PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） — Stella

Recruiting

Back to Hemophilia trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Institute of haematology and Blood diseases hospital, Tianjin, Tianjin Municipality

Key details

Phase

Post-approval study

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

North China University of Science and Technology, The Second Affiliated Hospital of Kunming Medical University

Enrollment target

~30 participants

Started

March 2026

Primary completion

December 2026

Age range

12 Years – 65 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov